|
1
|
Stang A and Jöckel KH: Trends in the
incidence of ocular melanoma in the United States, 1974–1998.
Cancer Causes Control. 15:95–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh AD, Bergman L and Seregard S: Uveal
melanoma: Epidemiologic aspects. Ophthalmol Clin North Am.
18:75–84. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Flaherty LE, Unger JM, Liu PY, Mertens WC
and Sondak VK: Metastatic melanoma from intraocular primary tumors:
The southwest oncology group experience in phase II advanced
melanoma clinical trials. Am J Clin Oncol. 21:568–572. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kujala E, Tuomaala S, Eskelin S and Kivelä
T: Mortality after uveal and conjunctival melanoma: Which tumour is
more deadly? Acta Ophthalmol. 87:149–153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alexandrescu DT, Ichim TE, Riordan NH,
Marincola FM, Di Nardo A, Kabigting FD and Dasanu CA: Immunotherapy
for melanoma: Current status and perspectives. J Immunother.
33:570–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jandus C, Speiser D and Romero P: Recent
advances and hurdles in melanoma immunotherapy. Pigment Cell
Melanoma Res. 22:711–723. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tripathi RK, Hearing VJ, Urabe K, Aroca P
and Spritz RA: Mutational mapping of the catalytic activities of
human tyrosinase. J Biol Chem. 267:23707–23712. 1992.PubMed/NCBI
|
|
8
|
Korner A and Pawelek J: Mammalian
tyrosinase catalyzes three reactions in the biosynthesis of
melanin. Science. 217:1163–1165. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cooksey CJ, Garratt PJ, Land EJ, Pavel S,
Ramsden CA, Riley PA and Smit NP: Evidence of the indirect
formation of the catecholic intermediate substrate responsible for
the autoactivation kinetics of tyrosinase. J Biol Chem.
272:26226–26235. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hearing VJ and Jiménez M: Mammalian
tyrosinase-the critical regulatory control point in melanocyte
pigmentation. Int J Biochem. 19:1141–1147. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiménez M, Maloy WL and Hearing VJ:
Specific identification of an authentic clone for mammalian
tyrosinase. J Biol Chem. 264:3397–3403. 1989.PubMed/NCBI
|
|
12
|
Jimenez M, Tsukamoto K and Hearing VJ:
Tyrosinases from two different loci are expressed by normal and by
transformed melanocytes. J Biol Chem. 266:1147–1156.
1991.PubMed/NCBI
|
|
13
|
Jackson IJ: A cDNA encoding
tyrosinase-related protein maps to the brown locus in mouse. Proc
Natl Acad Sci USA. 85:4392–4396. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boissy RE, Zhao H, Oetting WS, Austin LM,
Wildenberg SC, Boissy YL, Zhao Y, Sturm RA, Hearing VJ, King RA and
Nordlund JJ: Mutation in and lack of expression of
tyrosinase-related protein-1 (TRP-1) in melanocytes from an
individual with brown oculocutaneous albinism: A new subtype of
albinism classified as 'OCA3′. Am J Hum Genet. 58:1145–1156.
1996.PubMed/NCBI
|
|
15
|
Kobayashi T, Imokawa G, Bennett DC and
Hearing VJ: Tyrosinase stabilization by TRYP1 (the brown locus
protein). J Biol Chem. 273:31801–31805. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Manga P, Sato K, Ye L, Beermann F,
Lamoreux ML and Orlow SJ: Mutational analysis of the modulation of
tyrosinase by tyrosinase-related proteins 1 and 2 in vitro. Pigment
Cell Res. 13:364–374. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Vries TJ, Trancikova D, Ruiter DJ and
van Muijen GN: High expression of immunotherapy candidate proteins
gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer.
78:1156–1161. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shidham VB, Qi D, Rao RN, Acker SM, Chang
CC, Kampalath B, Dawson G, Machhi JK and Komorowski RA: Improved
immunohistochemical evaluation of micrometastases in sentinel lymph
nodes of cutaneous melanoma with ‘MCW melanoma cocktail’-a mixture
of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. BMC
Cancer. 3:152003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawakami Y, Robbins PF, Wang RF, Parkhurst
M, Kang X and Rosenberg SA: The use of melanosomal proteins in the
immunotherapy of melanoma. J Immunother. 21:237–246. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia R, Jiao Z, Xu X, Wang J, Zhou Y, Song
X, Ge S and Fan X: Functional significance of B7-H1 expressed by
human uveal melanoma cells. Mol Med Rep. 4:163–167. 2011.PubMed/NCBI
|
|
21
|
Song X, Zhou Y, Jia R, Xu X, Wang H, Hu J,
Ge S and Fan X: Inhibition of retinoblastoma in vitro and in vivo
with conditionally replicating oncolytic adenovirus H101. Invest
Ophthalmol Vis Sci. 51:2626–2635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boulton M and Dayhaw-Barker P: The role of
the retinal pigment epithelium: Topographical variation and ageing
changes. Eye (Lond). 15:384–389. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Smith-Thomas L, Richardson P, Thody AJ,
Graham A, Palmer I, Flemming L, Parsons MA, Rennie IG and MacNeil
S: Human ocular melanocytes and retinal pigment epithelial cells
differ in their melanogenic properties in vivo and in vitro. Curr
Eye Res. 15:1079–1091. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Flood MT, Gouras P and Kjeldbye H: Growth
characteristics and ultrastructure of human retinal pigment
epithelium in vitro. Invest Ophthalmol Vis Sci. 19:1309–1320.
1980.PubMed/NCBI
|
|
25
|
Newsome DA: Retinal pigmented epithelium
culture: Current applications. Trans Ophthalmol Soc UK.
103:458–466. 1983.PubMed/NCBI
|
|
26
|
Albert DM, Ruzzo MA, McLaughlin MA,
Robinson NL, Craft JL and Epstein J: Establishment of cell lines of
uveal melanoma. Methodology and characteristics. Invest Ophthalmol
Vis Sci. 25:1284–1299. 1984.PubMed/NCBI
|
